(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Oct. 28, 2026 (GLOBE NEWSWIRE) -- "Custom Recombinant Protein Production Services Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global custom recombinant protein production services market is experiencing rapid expansion as biopharmaceutical companies, biotechnology firms, contract research organizations, and academic institutions increase their reliance on specialized protein expression and purification capabilities. The market is projected to grow from $5.79 billion in 2025 to $6.47 billion in 2026, representing a compound annual growth rate (CAGR) of 11.8%.
Growth during the historical period was supported by the expansion of academic and clinical research, increased use of recombinant proteins in drug discovery, stronger biopharmaceutical research and development pipelines, greater availability of advanced expression technologies, and rising demand for specialized research services. Outsourcing has also enabled organizations to access technical expertise, production capacity, and quality assurance resources without making substantial investments in internal infrastructure.
The custom recombinant protein production services market is forecast to reach $10.21 billion by 2030, expanding at a CAGR of 12.1%. Key market drivers include the development of biologics and biosimilars, rising investment in precision medicine, increased outsourcing to contract research providers, growing demand for scalable protein production, and wider adoption of advanced purification technologies.
Prominent market trends include rising demand for custom protein expression services, greater use of mammalian expression systems, increased emphasis on high-purity protein production, faster project turnaround times, and more rigorous quality control and validation. Service providers are also expanding their capabilities across molecular cloning, expression optimization, protein purification, analytical characterization, and production scale-up to support increasingly complex research and therapeutic programs.
The growing focus on targeted and personalized therapies is expected to create significant opportunities for custom recombinant protein production service providers. Precisely engineered proteins are essential to biomarker research, patient-specific drug development, diagnostic applications, and advanced biologic therapies. Progress in precision medicine is increasing the need for reliable protein production platforms capable of meeting specialized structural, functional, purity, and scalability requirements.
Demand is reinforced by the rising number of personalized medicines entering clinical and commercial pipelines. According to the Personalized Medicine Coalition, the U.S. Food and Drug Administration approved 16 new personalized treatments for patients with rare diseases in 2023, compared with six in 2022. This increase highlights the expanding role of customized biologic research and the need for production partners that can support highly specific drug discovery and development programs.
Technology innovation remains a central competitive strategy in the custom recombinant protein production services market. Companies are investing in microbial and mammalian expression platforms designed to increase yield, improve protein stability, accelerate development timelines, and lower manufacturing costs. In March 2025, WuXi Biologics launched its EffiX Microbial Expression Platform for microbial-derived biologics. The platform reported titers exceeding 15 g/L for non-monoclonal antibody recombinant proteins and more than 1 g/L for plasmid DNA, supporting higher productivity and scalable development.
Industry consolidation is also strengthening integrated service offerings. In January 2025, NanoImaging Services acquired Proteos for an undisclosed amount. The transaction combines custom recombinant protein production expertise with advanced structural imaging and analytical capabilities. This integration is intended to provide a more comprehensive workflow for structure-based drug discovery, protein characterization, and pharmaceutical research.
The market covers antibodies, enzymes, cytokines, growth factors, and recombinant hormones produced through mammalian, bacterial, insect, yeast, and other expression systems. Applications span drug discovery, biopharmaceutical manufacturing, diagnostic development, academic research, and industrial enzyme production. Major end users include biotechnology and pharmaceutical companies, research institutions, contract research organizations, and other life sciences organizations requiring project-specific protein production.
Trade tariffs are influencing operating costs by raising prices for imported reagents, laboratory instruments, chromatography systems, bioreactors, and consumables used throughout protein expression and purification workflows. North American and European biotechnology and pharmaceutical organizations are particularly exposed because of their reliance on imported laboratory equipment, while Asia-Pacific service providers face higher costs when exporting specialized research services. Although tariffs can increase project expenses and extend procurement timelines, they are also encouraging domestic production of critical research materials, regional supplier partnerships, and investment in local laboratory infrastructure.
Markets Covered:
1) By Product: Antibodies; Enzymes; Cytokines; Growth Factors; Recombinant Hormones
2) By Expression System: Mammalian; Bacteria; Insect; Yeast; Other Expression Systems
3) By Application: Drug Discovery; Biopharmaceutical Production; Diagnostics Development; Academic Research; Industrial Enzymes
4) By End User: Research Institutes; Biotechnology and Pharmaceutical Companies; Contract Research Organizations (CROs); Other End-Users
Subsegments:
1) By Antibodies: Monoclonal Antibodies; Polyclonal Antibodies; Chimeric Antibodies; Humanized Antibodies; Single Chain Antibodies
2) By Enzymes: Proteases; Lipases; Amylases; Cellulases; Polymerases
3) By Cytokines: Interleukins; Interferons; Tumor Necrosis Factors; Colony Stimulating Factors; Chemokines
4) By Growth Factors: Epidermal Growth Factors; Fibroblast Growth Factors; Vascular Endothelial Growth Factors; Transforming Growth Factors; Platelet Derived Growth Factors
5) By Recombinant Hormones: Insulin; Erythropoietin; Growth Hormone; Thyroid Stimulating Hormone; Follicle Stimulating Hormone
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment